The North American Immune Tolerance Registry: Contributions to the thirty-year experience with immune tolerance therapy

Haemophilia

Volumn 15, Issue 1, 2009, Pages 320-328

  DiMichele, D ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Haemophilia A; Haemophilia B; Immune tolerance; Inhibitors

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; DEXAMETHASONE; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ALLERGIC REACTION; ALLERGY; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; HEMOPHILIA A; HEMOPHILIA B; HUMAN; HYPOALBUMINEMIA; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; LOW DRUG DOSE; MAINTENANCE THERAPY; MEDICAL SOCIETY; NEPHROSIS; NORTH AMERICA; PERIORBITAL EDEMA; PLASMAPHERESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; REGISTER;

FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HUMANS; IMMUNE TOLERANCE; ISOANTIBODIES; MALE; NORTH AMERICA; PROGNOSIS; REGISTRIES; TREATMENT OUTCOME;

EID: 63049130236     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01880.x     Document Type: Conference Paper

References (54)

1. Ehrenforth S, Kreutz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
2. Briet E, Reisner HM, Roberts HR. Inhibitors in Christmas disease. Prog Clin Biol Res 1984; 150: 123-9.
3. Aledort LM, Cohen M, Hilgartner M, Lipton R. Treatment of haemophiliacs with inhibitors: Cost and effect on blood resources. Prog Clin Biol Res 1984; 150: 353-65.
4. Brackmann HH, Gormsen J. Massive factor VIII infusion in a haemophiliac with factor VIII inhibitor, high responder (letter). Lancet 1977; 2: 933.
5. Brackmann HH. Induced immunotolerance in factor VIII inhibitor patients. Prog Clin Biol Res 1984; 150: 181-95.
6. Aznar JA, Jorquera JI, Peiro A, Garcia I. The importance of corticoids added to continued treatment with factor VIII concentrates in the suppression of inhibitors in haemophilia A. Thromb Haemost 1984; 51: 217-21.
7. Van Leeuwen EF, Mauser-Bunschoten EP, van Dijken PJ, Kok AJ, Sjamsvedin-Visset EJM, Sixma JJ. Disappearance of factor VIII:C antibodies in patients with haemophilia upon frequent administration of factor VIII in intermediate or low dose. Br J Haematol 1986; 64: 291-7.
8. Ewing NP, Sanders NL, Dietrich SL, Kasper CK. Induction of immune tolerance to factor VIII in haemophiliacs with inhibitors. JAMA 1988; 259: 65-8.
9. Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with haemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide and factor VIII. N Engl J Med 1988; 318: 947-50.
10. Gruppo RA, Valdez LP, Stout RD. Induction of immune tolerance in patients with haemophilia A and inhibitors. Am J Pediatr Hematol Oncol 1992; 14: 82-7.
11. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Low dose immune tolerance induction in haemophilia A patients with inhibitors. Blood 1995; 86: 983-8.
12. Kreuz W, Ehrenforth S, Funk M et al. Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow up. Haemophilia 1995; 1: 24-32.
13. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors - twenty years' 'Bonn Protocol'. Vox Sang 1996; 70: 30-5.
14. Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Jellberg K, Nilsson IM. Immunoadsorption for removal of inhibitors: Update on treatments in Malmo-Lund between 1980 and 1995. Haemophilia 1998; 4: 16-20.
15. Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Jellberg K, Nilsson IM. Tolerance induction using the Malmo treatment model 1982-1995. Haemophilia 1999; 5: 32-9.
16. Oldenburg J, Schwaab R, Brackmann HH. Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': Predictive parameter for therapy duration and outcome. Vox Sang 1999; 77: 49-54.
17. Nilsson IM, Berntorp E, Zetterval O. Induction of split tolerance and clinical cure in high-responding haemophiliacs with factor IX antibodies. Proc Natl Acad Sci USA 1986; 83: 9169-73.
18. Mariani G, Ghirardini A, Bellocco R. Immune tolerance in haemophilia. Principal results from the international registry. Thromb Haemost 1994; 72: 155-8.
19. Mariani G, Kroner B. International immune tolerance registry, 1997 update. Vox Sang 1999; 77: 25-7.
20. Kroner B. Comparison of the International Immune Tolerance Registry and the North American Immune Tolerance Registry. Vox Sang 1999; 77: 33-7.
21. DiMichele DM, Kroner BL and Members of the Factor VIII and IX Subcommittee. The North American Immune Tolerance Registry: Practices, outcomes, outcome predictors. Report of the FVIII IX subcommittee. Thromb Haemost 2002; 87: 52-7.
22. Soucie JM, Evatt B, Jackson D. Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. Am J Hematol 1998; 59: 288-94.
23. Walker I. Survey of the Canadian hemophilia population. Can J Public Health 1991; 82: 127-9.
24. DiMichele DM, Kroner B and the FVIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis. The maintenance of tolerance after successful immune tolerance induction in haemophilia A and B: The North American Registry. Haematologica 2000; 85(Suppl to No. 10): 40-4.
25. DiMichele DM, Hay CRM. The international immune tolerance study: A multicenter prospective randomised trial in progress. J Thromb Haemost 2006; 4: 2271-3.
26. Mariani G, Kroner B. Immune tolerance in haemophilia with factor VIII inhibitors: Predictors of success. Haematologica 2001; 86: 1186-93.
27. Astermark J, Morado M, Rocino A et al. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 2006; 12: 363-71.
28. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: Consensus recommendations. Haemophilia 2007; 13(Suppl 1): 1-22.
29. Hay CRM, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: A guideline from the United Kingdom Centre Doctors Organisation. Br J Haematol 2006; 133: 591-605.
30. Smith MP, Spence KJ, Waters EL et al. Immune tolerance therapy for hemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution. Thromb Haemost 1999; 81: 35-8.
31. Rocino A, Papa ML, Salerno E, Capasso F, Miraglia E, deBiasi R. Immune tolerance induction in hemophilia A patients with high-responding inhibitors to factor VIII: Experience at a single institution. Haemophilia 2001; 7: 33-8.
32. Orsini F, Rotschild C, Beurrier P, Faradji A, Goudemand J, Polack B. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica 2005; 90: 1288-90.
33. Barnes C, Rivard GE, Poon MC et al. Inhibitor Subcommittee of Association of Hemophilia Clinic Directors of Canada. Canadian multi-institutional survey of immune tolerance therapy (ITT) experience with the use of recombinant factor VIII for ITT. Haemophilia. 2006; 12: 1-6.
34. Lusher JM. Summary of clinical experience with recombinant factor VIII products-Kogenate. Ann Hematol 1994; 68(Suppl 3): S3-6.
35. Bray GL, Gomperts ED, Courter S et al. A multicenter study of recombinant factor VIII (Recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994; 83: 2428-35.
36. Batlle J, Lopez MF, Brackmann HH et al. Induction of immune tolerance with recombinant factor VIII in haemophilia A patients with inhibitors. Haemophilia 1999; 5: 431-5.
37. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. Semin Hematol 2001; 38(Suppl 4): 52-9.
38. Kurth MA, DiMichele D, Sexauer C et al. Immune tolerance therapy utilizing factor VIII/von Willebrand factor haemophilia A patient with high titre factor VIII inhibitors. Haemophilia 2008; 14: 50-5.
39. Greninger DA, Saint-Remy JM, Jacquemin M, Benhida A, DiMichele DM. The use of factor VIII/concentrate for immune tolerance induction in hemophilia A patients with high titer inhibitors: Association of clinical outcome with inhibitor epitope profile. Haemophilia 2008; 14: 295-302.
40. Ettingshausen CE, Kreuz W. Role of von Willebrand factor in immune tolerance induction. Blood Coagul Fibrinolysis 2005; 16(Suppl 1): 27-31.
41. DiMichele D, Kroner B. Higher Immune Tolerance (IT) success rate with monoclonal FVIII (mFVIII) when compared to recombinant (rFVIII): An analysis of The North American Immune Tolerance Registry (NAITR) [Abstract]. Blood 2000; 96: 266a.
42. Franchini M, Veneri D, Lippi G, Stenner R. The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders. Thromb Haemost 2006; 96: 119-25.
43. Stachnik JM. Rituximab in the treatment of acquired hemophilia. Ann Pharmacother 2006; 40: 1151-7.
44. Sperr WR, Lechner K, Pabinger I. Rituximab for the treatment of acquired antibodies to factor VIII. Haematologica 2007; 92: 66-71.
45. Collins PW. Novel therapies for immune tolerance in Haemophilia A. Haemophilia 2006; 12(Suppl 6): 94-101.
46. Thorland EC, Drost JB, Lusher JM, Warrier I, Shapiro A, Koerper M. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: Complete gene deletions confer the highest risk. Haemophilia 1999; 5: 101-5.
47. Ketterling RP, Vielhaber EL, Lind TJ, Thorland EC, Sommer SS. The rates and patterns of deletions in the human factor IX gene. Am J Hum Genet 1994; 54: 201-13.
48. Warrier I, Ewenstein BM, Koerper M et al. Factor IX inhibitors and anaphylaxis in haemophilia B. Am J Pediatr Hematol Oncol, 1997; 19: 23-7.
49. Warrier I. Factor IX antibody and immune tolerance. Vox Sang 1999; 77: 70-1.
50. Ewenstein BM, Takemoto C, Warrier I et al. Nephrotic syndrome as a complication of immune tolerance in haemophilia B (letter). Blood 1997; 89: 1115-6.
51. Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol 2004; 127: 379-91.
52. DiMichele DM. Immune tolerance: Critical issues of factor dose, purity and treatment complications. Haemophilia 2006; 12(Suppl. 6): 81-6.
53. DiMichele D. Inhibitor development in haemophilia B: An orphan disease in need of attention. Br J Haematol 2007; 138: 305-15.
54. Klarmann D, Martinez Saguer I, Funk MB et al. Immune tolerance induction with mycophenolate-mofetil in two children with haemophilia B and inhibitor. Haemophilia 2008; 14: 44-9.